Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2018; 24(36): 4104-4118
Published online Sep 28, 2018. doi: 10.3748/wjg.v24.i36.4104
Published online Sep 28, 2018. doi: 10.3748/wjg.v24.i36.4104
Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease
Jorge-Luis Torres, Laura Manzanedo, Ronald Macías, Francisco-Javier Laso, Miguel Marcos, Department of Internal Medicine, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca-IBSAL, Salamanca 37007, Spain
Jorge-Luis Torres, Ignacio Novo-Veleiro, Francisco-Javier Laso, Miguel Marcos, Spanish Working Group on Alcohol and Alcoholism, Spanish Society of Internal Medicine, Madrid 28016, Spain
Ignacio Novo-Veleiro, Department of Internal Medicine, University Hospital of Santiago de Compostela, A Coruña 15706, Spain
Lucía Alvela-Suárez, Department of Internal Medicine, HM Rosaleda Hospital, Santiago de Compostela, A Coruña 15701, Spain
Francisco-Javier Laso, Miguel Marcos, Department of Medicine, Faculty of Medicine, University of Salamanca, Salamanca 37007, Spain
Author contributions: Torres JL and Novo-Veleiro I contributed equally as first authors of this manuscript; Torres JL, Novo-Veleiro I, Manzanedo L, Alvela-Suárez L, Macías R and Marcos M carried out the literature research and drafted the manuscript; Torres JL, Novo-Veleiro I, Laso FJ and Marcos M contributed to manuscript conception and design; all authors approved the final version of the manuscript.
Supported by the Spanish Ministry of Science and Innovation , Instituto de Salud Carlos III and the European Union FEDER funds, Una manera de hacer Europa, (No. PI16/01548 to Miguel Marcos and No. RD16/0017/0023 to Francisco-Javier Laso) and Junta de Castilla y León GRS 1362/A/16 and INT/M/17/17 to Miguel Marcos and GRS 1587/A/17 to Jorge-Luis Torres) .
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Miguel Marcos, MD, PhD, Associate Professor, Staff Physician, Department of Internal Medicine, University Hospital of Salamanca, Paseo de San Vicente 182, Salamanca 37007, Spain. mmarcos@usal.es
Telephone: +34-923-291100-55437 Fax: +34-923-294739
Received: April 14, 2018
Peer-review started: April 14, 2018
First decision: May 21, 2018
Revised: June 25, 2018
Accepted: June 27, 2018
Article in press: June 27, 2018
Published online: September 28, 2018
Processing time: 164 Days and 5.1 Hours
Peer-review started: April 14, 2018
First decision: May 21, 2018
Revised: June 25, 2018
Accepted: June 27, 2018
Article in press: June 27, 2018
Published online: September 28, 2018
Processing time: 164 Days and 5.1 Hours
Core Tip
Core tip: MicroRNAs (miRNAs) are small RNAs that regulate gene expression at a post-transcriptional level. Altered miRNA expression has been found in a variety of liver diseases, including non-alcoholic fatty liver disease and alcoholic liver disease. A group of miRNAs (miR-155, miR-122 and miR-34a) contributes to the pathogenesis of these two diseases and these miRNAs have potential use as biomarkers or therapeutic targets. Several technical limitations and a lack of clinical studies, however, preclude their clinical use.